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1. Introduction 
Chemoattractant receptors are a superfamily of G-protein coupled seven transmembrane 
cell surface receptors (GPCRs), which transduce extracellular signals into intracellular 
effector pathways through the activation of heterotrimeric G proteins. This superfamily 
includes GPCRs for classical chemoattractants such as formyl peptides (fMLF) produced by 
Gram negative bacteria and host cell mitochondria, the complement cleavage components, 
leukotriene B4 (LTB4), and platelet activating factor (PAF) as well as GPCRs for chemokines 
(Le et al., 2002).  
Chemoattractant GPCRs have the ability to mediate directional migration of cells along a 
gradient of a chemoattractant. Initially, these receptors were identified mainly on 
leukocytes, where they play an important role in the trafficking of such cells to sites of 
inflammation and to lymphoid organs in immune responses (Le et al., 2004). However, 
during the past few years, both hematopoietic and nonhematopoietic cells have been found 
to express various chemoattractant GPCRs and are capable of migrating in response to 
agonists produced in tissue microenvironment. The interaction of chemoattractant GPCRs 
with their agonists participates in a variety of essential pathophysiological processes 
including immune responses, inflammation, host defense against microbial infection, 
hematopoiesis as well as cancer progression and metastasis (Huang et al., 2008).  
Chemoattractants and their GPCRs are widely expressed in the brain by neurons, glial and 
microglia cells. They are involved not only in cell migration during development and 
inflammation, but also act as regulators of neuronal survival, neurotransmission and cell-
cell communications (Ambrosini and Aloiso, 2004), as the third major transmitter system in 
the brain (Adler and Rogers, 2005). In addition, chemoattractants and their GPCRs are 
disregulated in neurodegenerative diseases, multiple sclerosis and brain tumors (Balkwill, 
2004; Ransohoff et al., 2007). A number of chemoattractant GPCRs have been detected in 
glioma cells including FPR1 and chemokine GPCRs (Table 1).  
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Chemoattractant 
GPCRs  
(expressing cells) 
Ligand (cell sources) Major effects on glioma References 
FPR1 (glioma cells) fMLF (bacteria);  
Annexin1(necrotic 
glioma cells) 
Growth; Invasion; 
Angiogenesis 
Zhou et al., 2005; 
Huang et al., 2007, 
2008, and 2010 
CXCR1  
(glioma cells) 
CXCL8 (glioma cells) Invasion  Raychaudhuri et al., 
2011 
CXCR2 
(glioma cells) 
CXCL8 (glioma cells) Angiogenesis Brat DJ et al., 2005 
CXCR3  
(glioma cells) 
CXCL10 (glioma cells) ; 
CXCL9 (glioma cells) 
Proliferation; Growth Liu et al., 2010;  
Maru et al., 2008 
CXCR4  
(glioma cells) 
CXCL12 (glioma cells 
and stromal cells) 
Growth; Angiogenesis; 
Migration  
Ping et al., 2007 and 
2011 
CXCR5 
 (glioma cells) 
CXCL13 (glioma cells) Not clear Bajetto et al., 2006 
CXCR7  
(glioma cells) 
CXCL12 (glioma cells 
and stromal cells) 
Anti-apoptosis Hattermann et al., 2010 
CCR2A 
(glioma cells) 
CCL2 (glioma cells) Migration Liang Y et al., 2008 
CCR3 (glioma cells) CCL3L1 (glioma cells) Proliferation Kouno et al., 2004 
CCR4 (Treg cells) CCL22 (glioma cells) Treg infiltration Jacobs et al., 2010  
CCR5 (glioma cells) CCL3L1 (glioma cells) Proliferation Kouno et al., 2004 
CX3CR1 
(glioma cells and 
GIMs) 
CX3CL1 (glioma cells) Tumorigenesis; Pro-or 
anti-invasion based on 
whether CX3CL1 is  
soluble or membrane 
bound.  
Liu et al., 2008 
GIMs: glioma infiltrating macrophages; Treg: regulatory T cells.  
Table 1. The expression of chemoattractant GPCRs in glioma 
Glioma is the most common tumor type in human brain. Nearly two-thirds of human 
gliomas are highly malignant with rapid progression, high invasiveness, vigorous 
angiogenesis and resistance to chemotherapy and radiation treatment (Bar, 2011). 
Glioblastoma (GBM), the most aggressive form of malignant glioma, is characterized by 
extensive infiltration into the surrounding normal brain tissues and multifocal necrosis. 
Despite multiple therapeutic regimens (Jahraus and Friedman, 2010), the 2-year survival 
rate of patients with GBM is less than 30% and has not changed over the past two decades. 
Because of the increasing incidence of GBM and very poor prognosis, a better 
understanding of GBM initiation and progression is crucial for the development of more 
effective therapeutic approaches. GBM cells utilize the normal physiological functions of 
chemoattractant GPCRs to promote their growth by sensing cognate ligands produced in 
the microenvironment that enhance tumor cell proliferation, invasion and the production of 
angiogenic factors such as vascular endothelial cell growth factor (VEGF) and the 
chemokine CXCL8 (IL-8) (Yao et al., 2008; Ping et al., 2007). Recently, the chemoattractant 
GPCRs FPR1 and CXCR4 were also found to be expressed by glioma stem-like cells (GSLCs) 
and to mediate GSLC chemotaxis and the production of VEGF (Ping et al., 2007; Yao et al., 
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2008; Ping et al., 2011), suggesting the important role of these GPCRs in glioma initiation. In 
this article, we will review the contribution of chemoattractant GPCRs in glioma progression 
and discuss the potential for GPCRs as therapeutic targets in glioma.  
2. The role of the classical chemoattractant GPCR, FPR1, in the progression 
of GBM  
2.1 Identification of FPR1 in GBM 
Human FPR1 (originally named FPR) was detected in 1976 on the surface of human 
neutrophils, and was cloned in 1990 from a myeloid leukemia-cell line. FPR1 binds N-
formyl-methionyl-leucyl-phenylalanine (fMLF), a product of the Gram negative bacteria, as 
well as mitochondria formylated peptide, and elicits a cascade of signal transduction events 
mediated by pertussis toxin-sensitive G proteins of the Gi subtype and controlled by 
phospholipase C (PLC) and phosphoinositide (PI) 3 kinases (Pan et al., 2000). Human 
myeloid cells activated by FPR1 agonist peptides undergo rapid shape change, showing 
increased adhesion, chemotaxis, phagocytosis and release of bactericidal and 
proinflammatory mediators. These functions of FPR1 enable myeloid cells to have 
proinflammatory and antimicrobial activities. In fact, depletion of the human FPR1 
counterpart mFPR1 from mice decreased their resistance to infection by Listeria 
monocytogenes. Although FPR1 has been shown to be a GPCR that mediates host defense 
against bacterial infection by phagocytic leukocytes, we found that FPR1 was also selectively 
expressed by tumor cells in more highly malignant human glioma specimens (Zhou et al., 
2005). These findings prompted us to use established human glioma cell lines to investigate 
the relationship between FPR1 expression and the biological behavior of the tumor cells. For 
example, the human GBM cell line U87 expresses higher levels of FPR1 and forms more 
rapidly growing tumors in nude mice than glioma cell lines derived from low grade 
gliomas, which do not express FPR1 (Zhou et al., 2005). Therefore, observations with glioma 
cell lines lead us to hypothesize that FPR1 is selectively expressed by more highly malignant 
glioma cells and may play a role in promoting tumor growth.  
2.2 Function of FPR1 in GBM cells 
The function of FPR1 in GBM cells was extensively examined by using the prototype 
chemotactic agonist peptide, bacterial fMLF as a stimulator. In addition to inducing robust 
chemotaxis and calcium mobilization of GBM cells by fMLF, FPR1 exhibited several unique 
properties that are closely related to tumor progression. For instance, activation of FPR1 in 
GBM cells under suboptimal culture conditions (i.e. at low fetal calf serum (FCS) 
concentration) supports the survival of tumor cells in association with increased 
intracellular levels of the anti-apoptotic protein Bcl-2. In addition, FPR1 agonist peptide 
activated two important transcription factors, namely NF-κB and STAT3 in GBM cells. 
Increased NF-κB translocation has been observed as a consequence of FPR1 signaling 
pathway also in phagocytic leukocytes (Huang et al., 2001); FPR1 signaling in GBM cells 
stimulated the phosphorylation of STAT3 at Ser-727 and Tyr-105 residues, while only Ser-
727 was phosphorylated in human monocytes. Another transcription factor hypoxia 
inducible factor-1ǂ (HIF-1ǂ), which induces the adaptation to hypoxic microenvironment by 
regulating the gene transcription in several processes such as cell oxygen uptake, glucose 
metabolism, angiogenesis, cell survival and apoptosis, was also activated by FPR1 agonists 
in GBM cells (Zhou et al., 2005).  
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Since both STAT3 and HIF-1ǂ are implicated in the transcriptional activation of the gene 
coding for VEGF, we investigated the effect of activating FPR1 on the production of VEGF 
by tumor cells. We found that supernatants from fMLF-stimulated GBM cells induced the 
migration and tubule formation of human vascular endothelial cells (EC) (Zhou et al., 2005). 
This property of the tumor cell supernatant was abolished by a neutralizing anti-human 
VEGF antibody (Zhou et al., 2005), suggesting VEGF was released by FPR1 agonist-
stimulated GBM cells. FPR1 in GBM cells was subsequently shown to promote the release of 
another angiogenic factor, the chemokine CXCL8 (IL-8) (Yao et al., 2008). The contribution of 
FPR1 to GBM progression was then tested in vivo in nude mice. Tumor cells containing 
small interference (si) RNA targeting FPR1 mRNA yielded tumors in nude mice with 
markedly reduced rate of growth as compared to control cells transfected with random 
siRNA (Zhou et al., 2005). Thus, the functional studies provide strong evidence for the 
involvement of FPR1 in supporting the rapid progression of GBM.  
Crosstalk between GPCRs and growth factor receptors plays an important role in orchestrating 
the interaction of intracellular signaling molecules implicated in tumor growth, angiogenesis 
and metastasis (Lappano and Maggiolini, 2011). The crosstalk between GPCRs and the 
receptor for epidermal growth factor (EGFR) has been shown to promote the progression of 
colon, lung, breast, ovarian, prostate, and head and neck carcinomas (Hart et al., 2005). Like 
many malignant tumors of human and mouse origin, human GBM cells express high levels of 
EGFR and stimulation with EGF increases tumor cell chemotaxis and proliferation with rapid 
phosphorylation of at least 4 tyrosine residues in the C-terminal domain of EGFR (Huang et 
al., 2007). When GBM cells were stimulated with the FPR1 agonist fMLF, EGFR was also 
rapidly phosphorylated but with restriction to a single tyrosine residue Tyr992. This 
transactivation of EGFR by FPR1 agonist peptide accounted for approximately 40% of the 
biological activity of FPR1 in GBM cells and was dependent on a Src kinase pathway (Huang 
et al., 2007). Moreover, GBM cells depleted of either FPR1 or EGFR grew more slowly as 
compared with parental cells and depletion of both receptors further reduced the 
tumorigenicity of the GBM cells (Huang et al., 2007). Thus, FPR1 aberrantly expressed in GBM 
cells is capable of exploiting the function of EGFR to exacerbate the malignant behavior of the 
tumor cells. Since interference with both receptors additionally reduced tumor growth, FPR1 
and EGFR also had non-redundant functions (Huang et al., 2008).  
2.3 The involvement of FPR1 in GBM cell invasion 
The ability of GBM cells to invade into surrounding brain tissue is a critical pathological 
event in the progression of GBM. In the human GBM cell line U87, there are FPR1+ and 
FPR1- subpopulations which could be isolated and cloned. FPR1+ cells showed a more 
“motile” phenotype in vitro as compared with cells lacking FPR1 expression (Huang et al., 
2010). Moreover, although both FPR1+ and FPR- GBM cells implanted subcutaneously into 
nude mice developed tumors, only tumors formed by FPR1+ cells invaded the surrounding 
connective tissues. In addition, FPR1- cells transfected with FPR1 showed enhanced 
mobility in vitro and the in vivo capacity to form more rapidly growing and invasive 
tumors in mice. Tumor invasion depends not only on tumor cell mobility, but also on the 
capacity of tumor cells to secrete metal matrimetalloproteases (MMPs) that degrade 
extracellular matrix (ECM) and facilitate the detachment of highly motive tumor cells. 
Stimulation of GBM cells with FPR1 agonist peptide up-regulates the expression of MMP2 
and MMP9 and increases the release of pro-MMP2. As reported in the literature, regulation 
of MMPs is controlled by AP1 transcription factor complex through MAP kinase pathways 
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and PKC, which are activated by FPR1 agonist in GBM cells. Thus stimulation of FPR1 
activates MMPs in GBM cells and increases proteolytic processes in the tumor 
microenvironment (Huang et al., 2010).   
2.4 Identification of endogenous FPR1 agonist released by necrotic GBM cells  
Despite extensive characterization of FPR1 function in GBM cells, whether host-derived 
agonists are present in the tumor microenvironment remains unknown. We tested GBM cell 
responses to the neutrophil granule protein cathepsin G, which is an endogenous agonist for 
FPR1 and induces the migration of myloid cells. We determinated that cathepsin G is 
capable of inducing the migration of GBM cells expressing FPR1 (Sun et al., 2004). However, 
cathepsin G is unlikely to be present in brain unless substantial tissue damage compromises 
the blood brain barrier and results in the release of this FPR1 agonist into the brain by 
neutrophils. We therefore examined other possible sources of potential FPR1 agonists that 
may act on GBM cells. Since mitochondrial peptides are also potential endogenous FPR1 
agonists and GBMs frequently contain necrotic foci in the rapidly growing tumor mass that 
may release mitochondrial components, we examined the presence of FPR1 agonists in 
supernatants of necrotic tumor cells. Indeed, supernatants of necrotic GBM cells and tumors 
formed by GBM cells in nude mice induced potent chemotaxis of live GBM cells as well as a 
rat basophil leukemia-cell line transfected to express human FPR1 (ETFR cells). The 
chemotactic activity released by necrotic GBM cells and tumor tissues was blocked by an 
anti-FPR1 antibody and by a FPR-specific antagonist tBoc-MLF (Zhou et al., 2005). The 
robust intracellular Ca2+ mobilization induced in GBM cells by necrotic GBM cell 
supernatant attenuated the subsequent cell response to fMLF, suggesting that agonist 
contained in the supernatants of necrotic tumor cells share a receptor with fMLF (Zhou et 
al., 2005). Further evidence to support the release of FPR1 agonists by necrotic GBM cells 
was provided by the observation that the tumor cell supernatant down-regulated FPR1 
expressed on the surface of human monocytes and FPR1 expressing ETFR cells. These 
observations confirm that FPR1 expressed on GBM cells is able to recognize agonist activity 
released in the tumor microenvironment in a paracrine and/or autocrine loop (Zhou et al., 
2005). Our recent effort to characterize the biochemical nature of the FPR1 agonist activity 
released by necrotic GBM cells revealed that the glucocorticoid binding protein annexin1 
(AnxA1), which has been reported to be an agonist for FPR1 and its variant receptor FPR2, 
can promote tumor cell invasion and angiogenesis. AnxA1 accounts for the majority of the 
FPR1 agonist activity released by necrotic GBM cells because depletion of AnxA1 from the 
necrotic tumor supernatant markedly reduced its capacity to stimulate FPR1 on viable GBM 
cells (Yang et al., unpublished observation). We therefore established a paradigm for the 
role of FPR1 in GBM progression in which FPR1 in GBM cells by responding to necrotic 
tumor cell-released agonist such as AnxA1 transactivates EGFR and the two receptors co-
operate to promote the growth, invasion, angiogenesis and progression of GBM (Fig 1A). 
3. The role of the chemokine GPCR CXCR4 in glioma progression 
3.1 CXCR4 and its ligand CXCL12  
CXCR4 selectively binds the CXC chemokine stromal cell-derived factor 1 (SDF-1), also 
known as CXCL12 (Furusato et al., 2010). CXCR4 is normally expressed in a wide variety of 
cells and tissues. The CXCR4 agonist CXCL12 was first cloned from a murine bone marrow 
stromal cell line, and was produced in high quantity by marrow stromal cells. In addition to 
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mediating cell chemotaxis in response to CXCL12, CXCR4 also acts as a co-receptor for CD4 
cell entry of T tropic HIV. In mouse models, deletion of CXCL12 or CXCR4 results in 
embryonic death with defects in the development of cardiac and central nervous systems as 
well as reduction in hematopoietic stem-cell homing (Zou et al., 1998). CXCR4 is up-
regulated in more than 20 different types of malignant tumors (Kryczek et al., 2007). Further 
studies show that CXCR4 regulates tumor progression by mediating tumor cell proliferation 
and metastasis as well as angiogenesis.  
3.2 The effect of CXCR4 on glioma invasion and metastasis 
CXCR4 expression was detected in primary human glioma specimens and the level of 
CXCR4 was correlated with the degree of malignancy of the tumors. In vitro, CXCR4+ 
malignant glioma cells secrete its ligand CXCL12, suggesting that two molecules may exert 
paracrine and autocrine regulation of glioma progression (Bajetto et al., 2006). Studies 
performed in human GBM specimens demonstrated that tumor cells infiltrating into 
surrounding brain tissues express higher levels of CXCR4, suggesting CXCR4 expression 
may define more highly invasive tumor cells. This is corroborated by in vitro experiments 
showing that invasive human glioma cells overexpress CXCR4 as compared with 
noninvasive tumor cells (Ehtesham et al., 2006). Invasive cells isolated from rat C6 glioma 
cell line express both CXCR4 and CXCL12 at high levels (Ehtesham et al., 2006). Moreover, 
application of CXCR4 antagonist or siRNA targeting CXCR4 in vivo inhibited the invasion 
of tumors formed by invasive C6 glioma cells.  
The invasion process of GBM requires the detachment of invading cells from tumor mass, 
attachment of tumor cells to ECM components, ECM degradation, and subsequent cell 
infiltration into surrounding brain tissues. Attachment of tumor cells to ECM components is 
an essential phase of invasion mediated by integrins that are overexpressed on both glioma 
cells and tumor vasculature. Recognition of CXCL12 by CXCR4 activates tumor-associated 
integrins, such as ǂ2, ǂ4, ǂ5, and ǃ1 to promote tumor dissemination (Hartman et al., 2004, 
and 2005). Inhibition of integrin function disrupts GBM cell migration. In vitro, interference 
of CXCR4 with the urokinase-receptor (uPAR) reduces the adhesion of CXCL12-mediated 
CXCR4+ GBM cells to collagen, the main component of ECM (Montuori et al., 2010).  
ECM degradation by MMPs enhances tumor invasion. In vitro, glioma cells with lower 
production of MMP-9 show diminished migration and invasion and such cells no longer 
form tumors following intracranial injection into nude mice. MMP-2 and -9 have been 
identified as MMPs in high grade gliomas and their level of expression directly correlates 
with the grade of glioma malignancy (Stojic et al., 2008). Similar to FPR1, CXCR4 mediated 
glioma invasion in vivo was also associated with its capacity to activate MMPs (Kryczek et 
al., 2007). It has been reported that CXCR4/ERK/NF-κ B signaling pathway induces the up-
regulation of MMPs in glioma cells. Activation of CXCR4 by its ligand CXCL12 also 
promotes tumor invasion by release of MMP-9. 
3.3 CXCR4 in glioma growth and angiogenesis  
3.3.1 Role of CXCR4/CXCL12 in malignant glioma growth and survival  
The CXCR4 ligand CXCL12 produced by tumor and stromal cells interacting with CXCR4 
on tumor cells results in the activation of several downstream pathways, including 
MAPK/ERK1/2, PI3k and Akt, as well as NF-κB. These pathways are known to participate 
in the regulation of cell proliferation and survival in normal or malignant glial cells. In vitro 
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activation of CXCR4 promotes the proliferation of GBM cell lines based on the activation of 
ERK1/2 and PI3K/Akt (Bian et al., 2007). In agreement with data obtained from GBM cell 
lines, 80% of clinical GBM samples express high levels of phosphorylated Akt 
(Hambardzumyan et al., 2008). CXCL12 induces the proliferation of primary GBM cells 
expressing CXCR4 by significantly increasing DNA synthesis in tumor cells (do Carmo et 
al., 2010). CXCR4-mediated tumor cell proliferation may also be amplified by EGFR 
signaling, since stimulation of CXCR4 has been reported to transactivate EGFR in many 
tumors of the epithelial lineage (Dolce et al., 2011). In fact, as discussed earlier, EGFR in 
GBM cells is transactivated by another chemoattractant GPCR FPR1, and the two receptors 
co-operate to promote the growth of GBM (Huang et al., 2007). The role of CXCR4 in 
promoting glioma growth was further supported by the use of a small molecule CXCR4 
antagonist, AMD3100, which significantly inhibited tumor cell proliferation in vitro and 
tumorigenicity in nude mice (do Carmo et al., 2010; and Dolce et al., 2011).  
Another important property of CXCR4 is to increase GBM cell resistance to apoptosis. 
Blockade of CXCR4 in glioma cells by the antagonist AMD3100 increased the rate of 
apoptosis, confirming the ability of CXCR4 to support tumor cell survival (do Carmo et al., 
2010). This anti-apoptotic effect is associated with the activation of PI3K/Akt (do Carmo et 
al., 2010), an observation consistent with results obtained from a variety of tumors in which 
CXCR4 actively contributes to the resistance of tumor cells to apoptosis. Stimulation of 
CXCR4 activates NF-κB, which in turn inhibits radiation-induced TNF-ǂ production by 
glioma cells and increases tumor cell survival. In addition to directly protecting tumor cells 
from radiation-induced apoptosis, CXCR4 indirectly promotes cell survival by increasing 
their adherence. For example, stimulation of CXCR4 promotes the adhesion of glioma cells 
to vitronectin, a glioma-derived extracellular matrix protein, and prevents tumor cell death 
(do Carmo et al., 2010). Taken together, published results support the conclusion that 
CXCR4 plays an important role in promoting the proliferation and survival of glioma cells.  
3.3.2 CXCR4 promotes the production of angiogenic factors by glioma cells 
The requirement of CXCR4 and CXCL12 for angiogenesis was revealed by the prenatal 
lethal phenotype of both CXCR4 and CXCL12 knockout mice due to defects in the vascular 
development of gastrointestinal tract and cardiogenesis (Tachibana et al., 1998). In vitro, 
activation of CXCR4 in ECs stimulates the formation of capillary-like tubules (Salvatore et 
al., 2010). ECs in gliomas have been shown to be genetically and functionally distinct from 
normal ECs, and exhibit higher expression of CXCR4 and its ligand CXCL12. Proliferating 
ECs in GBM are positive for CXCR4 and its ligand CXCL12, while ECs that form a single 
layer in the capillaries of the anaplastic astrocytoma appeared to be negative for these two 
molecules. The lower levels of CXCR4/CXCL12 expression in anaplastic astrocytoma may 
contribute to the lower density of proliferating microvasculature. Consistent with these 
observations, CXCR4 and CXCL12 are detected in both malignant glioma cells and vascular 
ECs are associated with increased cell survival (Salmaggi et al., 2004). 
Interestingly, elevated CXCL12 levels by themselves in gliomas failed to induce significant 
vascularization. This was associated with the co-presence of low levels of VEGF, suggesting 
synergism of these angiogenic factors (Kryczek et al., 2005). In fact, although a major 
angiogenic factor in GBM, VEGF was detected only in a few cells or not at all in low-grade 
astrocytomas or in the normal brain tissue (Takano et al., 2010). Clinical and experimental 
evidence indicates that CXCR4 activation induces the production of VEGF in human glioma 
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cells and glioma stem-like cells (Ping et al., 2007 and 2011). Therefore, CXCR4 may 
contribute to the production of VEGF by malignant glioma cells and the two pro-angiogenic 
factors synergistically promote angiogenesis in tumor. In addition to VEGF, the activation of 
CXCR4 in gliomas also is associated with increases the secretion of an angiogenic 
chemokine, CXCL8 (IL-8) (Ping et al., 2007). Interestingly, VEGF binds the receptors on ECs 
and leads to the up-regulation of the anti-apoptotic molecule Bcl-2 as well as the release of 
CXCL8 from ECs (Nör et al., 2001). CXCL8 then is capable of maintaining the angiogenic 
phenotype of ECs in an autocrine and paracrine manner (Nör et al., 2001; Heidemann et al., 
2003). In addition, the activation of CXCR4 also results in NF-κB translocation in glioma 
cells, which elicits the production of other angiogenic chemokines, such as CXCL1, CXCL2, 
and CXCL5 (Richmond et al., 2002). Therefore, glioma angiogenesis is the result of a well-
coordinated process participated in by multiple angiogenic factors among which CXCR4 
appears to be an upstream initiator.  
3.3.3 CXCR4/CXCL12 mediates vasculogenesis by mobilizing bone marrow derived 
progenitor cells  
In addition to tumor angiogenesis, which is thought to be established by the sprouting of 
blood vessels through the division of normal differentiated host ECs present in the tissue 
adjacent to tumor, another way to generate tumor vessels is through the process of 
vasculogenesis, which is formed by the recruitment of circulating EC precursor cells or bone 
marrow-derived cells (BMDCs) (Garcia-Barros et al., 2003). Circulating EC progenitor cells 
mobilized from the bone marrow are normally present in the peripheral blood of several 
species and participate in the neovascularization in tumor and in ischemic tissues (Spaeth et 
al., 2009). CXCR4 has been demonstrated to guide prime stem cells to the sites of rapid 
vascular expansion during embryonic organogenesis (Napoli et al., 2010). The pivotal role of 
CXCR4 and its ligand CXCL12 in vasculogenesis has been demonstrated in gene deletion 
mice as discussed earlier.  
Similar to the development of embryonic vessels, CXCR4 mediates tumor 
neovascularization by switching from angiogenesis in the recurrent malignant glioma to 
vasculogenesis. For instance, tumor growth supported mainly by angiogenesis from nearby 
normal vessels is abrogated by irradiation (Kioi et al., 2010). As a consequence, the growth 
of new tumor vasculature in irradiation animals will rely mainly on circulating blood EC 
progenitor cells from the bone marrow. Studies have demonstrated that CXCR4 is a key 
factor for the influx of BMDCs into the recurrent tumor after irradiation, since both the 
CXCR4 inhibitor AMD3100 and antibodies against CXCR4 are able to block the recruitment 
of BMDCs into tumor and prevent the restoration of the vasculature (Kioi et al., 2010). 
Hypoxia also mediates tumor vasculogenensis through CXCR4 in animal models. 
Irradiation results in a hypoxic microenvironment in the tumor resulting in the up-
regulation of the transcription factor HIF-1 (Ahn and Brown, 2008) and enhanced 
production of CXCL12 and VEGF. CXCL12 then induces the homing of CD11b+ BMDCs 
into the tumor site to initiate the formation of new vasculature (Kioi et al., 2010).  
4. CXCR7/CXCL12  
4.1 CXCR7 expression in glioma 
Although it was believed that CXCL12 uses CXCR4 as a sole receptor, recent studies have 
shown that CXCR7, a newly identified chemokine GPCR, acts as an alternate receptor for 
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CXCL12 and for another chemokine e.g. interferon-inducible T cell ǂ chemoattractant (I-
TAC; also known as CXCL11). CXCR7 is expressed in several tumors and plays an 
important role in preventing tumor cell apoptosis and promoting tumor cell adhesion to 
ECs, a key step for the development of blood-borne metastasis (Burns et al., 2006). In glioma 
specimens, CXCR7 is widely distributed in tumor cells, microglia and ECs. In contrast, 
CXCR4 seems to be restricted to certain subsets of glioma cells and tumor stem-like cell 
populations. While the CXCR4 level is significantly higher in GBM than in lower grade 
gliomas, no distribution difference was detected for CXCR7 (Hattermann et al., 2010). One 
study reported that in eight glioma cell lines tested, only one expresses CXCR4. However, 
CXCR7 is highly expressed in all glioma cell lines (Hattermann et al., 2010). Interestingly, 
tumor stem-like cells derived from GBM cell line express CXCR4, but not CXCR7. In 
addition, differentiated glioma cells often are found to express CXCR7, but not CXCR4. 
These observations suggest that there is a difference between the role of CXCR4 and CXCR7 
in the function of glioma cells. In some tumors, CXCR7 and CXCL12 are co-localized and 
potentially cooperate in tumor progression (Hattermann et al., 2010). 
4.2 CXCR7 may mediate glioma progression  
Initially, CXCR7 was regarded as a decoy receptor that recognizes CXCL12 or a coreceptor 
that may form a heterodimeric complex with CXCR4 to enhance CXCL12 signaling in 
embryonic cells. Subsequently, CXCR7 was demonstrated to be functionally active in glioma 
cells. CXCR7 activation by CXCL12 stimulates a transient phosphorylation of ERK1/2 and 
inhibits the apoptosis of glioma cells induced by camptothecin and temozolomide, but did 
not increase tumor cell proliferation and migration (Hattermann et al., 2010). CXCR7 
activation also did not elicit calcium mobilization in tumor cells, but increases their adhesion 
(Burns et al., 2006). The absence of ligand-induced calcium influx and cell migration 
distinguishes the CXCR7 signaling pathway from CXCR4 and other typical chemokine 
GPCRs. In cells transiently transfected with human CXCR7 and rat cells expressing CXCR7, 
the signaling of CXCR7 is not mediated by Gǂi protein, but by ǃ-arrestins associated with 
the phosphorylation of MAP kinases (Rajagopal et al., 2010). Based on these properties of 
CXCR7, it is assumed that some of the previously reported effects of CXCL12 on glioma 
cells, such as phosphorylation of kinases and prevention of apoptosis might be partially 
mediated by CXCR7. Since ECs isolated from GBM express high levels of CXCR7 mRNA, it 
is postulated that CXCR7 may be involved in the formation of glioma vasculature (Takano 
et al., 2010). Indeed, in many CXCR7+ tumors, VEGF and CXCL8 (IL-8) are up-regulated. 
Therefore, CXCR7 is a novel chemokine GPCR that promotes glioma progression by 
supporting tumor cell survival, adhesion and possibly vessel formation. 
4.3 Potential interactions between CXCR7 and CXCR4 
Accumulating evidence suggests that CXCR7 and CXCR4 interact with each other in 
malignant tumors. In human rhabdomyosarcomas (Grymula et al., 2010), downregulation of 
CXCR7 expression by hypoxia was thought to increase CXCL12 signaling through CXCR4 
thus rendered rhabdomyosarcoma cells more motile and prone to detach from the primary 
tumor. Confocal microscopy shows that in glioma cell lines, CXCR7 is mainly localized in 
the space between the plasma membrane and endosomal compartment, whereas CXCR4 is 
mostly present on the cell surface of membrane (Calatozzolo et al., 2011). The biological 
significance of the distinct pattern of CXCR7 and CXCR4 expression in glioma cells is not 
clear. However, in somatic cells, CXCR7 facilitates CXCR4-mediated migration of 
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primordial germ cells by controlling the level of CXCL12 in the microenvironment to form a 
chemotactic gradient (Boldajipour et al., 2008). In HeLa cells, CXCR7 acts as a scavenger 
receptor for CXCL12, which results in the internalization of CXCL12 and the subsequent 
reduction of CXCR4 activity (Naumann et al., 2010). An alternative mechanism by which 
CXCR7 regulates CXCR4 activity may be its potential to form heterodimer with CXCR4. In 
fact, some studies have shown changes in CXCR4 signaling by heterodimerization with 
CXCR7. Although the precise mechanisms of interaction between CXCR7 and CXCR4 and 
the consequences in glioma progression remain to be determined, the available results 
suggest an important role for CXCR7 in regulating the activity of the more ubiquitously 
expressed CXCR4 in gliomas (Fig. 1B). 
5. CX3CR1/CX3CL1 in glioma progression 
Another chemoattractant GPCR CX3CR1 and its agonist CX3CL1 have also been reported to 
play a role in glioma progression. CX3CL1 is one of the most highly expressed chemokines 
in the brain (Bazan et al., 1997) and is a peculiar member of the chemokine family which can 
mediate both chemotaxis and adhesion of inflammatory cells via its highly selective receptor 
CX3CR1. CX3CR1 is overexpressed in gliomas at both mRNA and protein levels, regardless 
of tumor classification and clinical severity, while CX3CL1 expression is correlated with 
glioma grade and overall patient survival (Locatelli et al., 2010). CX3CL1 is more highly 
expressed in tumor area near sites of necrosis suggesting that necrosis may directly enhance 
CX3CL1 transcription in tumor cells, or indirectly via inflammatory cytokines released by 
necrotic cells, including TNFǂ, which is a potent stimulant of CX3CL1 transcription 
(Marchesi et al., 2010). The increased expression of CX3CL1 in higher grade gliomas implies 
the involvement of CX3CL1 and its receptor CX3CR1 in tumor progression. CX3CR1 and 
CX3CL1 contribute to glioma progression in two ways: (1) by affecting the host defense 
mediated by immune cells and (2) by directly promoting tumor cell proliferation.  
5.1 The role of CX3CR1 in immune cell activation in the brain 
In colorectal cancer patients, high expression of CX3CR1 in tumor tissue is correlated with 
increased density of tumor infiltrating lymphocytes, which is associated with more 
favorable prognosis (Dimberg et al., 2007). CX3CR1 deficient mice bearing B16 melanoma 
are reported to show increased lung tumor metastasis and cachexia as well as reduced 
recruitment of monocytes and NK cells into the tumor (Yu et al., 2007). Thus, CX3CR1 may 
promote the infiltration of immune cells with antitumor activity.  
Glioma-infiltrating microglia/macrophages (GIMs) are the major component in the stroma 
of glioma tumors and these cells express CX3CR1. In vitro, activation of CX3CR1 in GIMs 
isolated from human glioma specimens increases these cell adhesion and migration in 
response to CX3CL1 (Held-Feindt et al., 2010). Blocking CX3CR1 by a specific antibody 
reduced the migration of GIMs in response to the conditioned medium containing CX3CL1 
secreted by human GBM cell lines (Held-Feindt et al., 2010). However, GIMs in glioma 
stroma did not mediate antiglioma immune responses (Liu et al., 2008). In fact, GIMs are 
characterized by a phenotype that may potentially promote tumorigenesis, i.e., more likely 
functioning as type Ⅱ macrophages. Also, CX3CR1 activation increases the expression of 
MMP2, 9 and 14 in GIMs, which may not only favor the migration and adhesion of GIMs, 
but also the infiltration of normal brain tissue by tumor cells (Markovic et al., 2005).  
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5.2 The direct effect of CX3CR1 on glioma cells 
Since CX3CL1 and CX3CR1 are co-expressed by glioma cells, they are hypothesized to play 
a role in glioma growth in an autocrine loop. However, the interaction of CX3CR1 with 
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Fig. 1. The role of chemoattractant GPCRs in glioma progression. A. FPR1 and EGFR 
cooperate to exacerbate the progression of GBM. FPR1 in GBM cells was activated by 
agonists released by necrotic tumor cells to promote GBM cell survival, invasion and 
angiogenesis. The FPR1 function in GBM cells is mediated in part by transactivation of 
EGFR through a Src kinase pathway. B. Interaction of CXCR4 with CXCL12 produced by 
glioma cells and stromal cells promotes the proliferation, invasion and angiogenesis of 
tumor. The activity of CXCL12 may be partially mediated by another CXCL12 receptor 
CXCR7. C. CX3CL1 secreted by glioma cells increases the infiltration of microglia 
/macrophages expressing CX3CR1 and promotes tumor progression. Interaction of CX3CR1 
with CX3CL1 produced by glioma cells increases cell-cell adhesion in tumor that inhibits the 
invasion of tumor cells. However tumor cells activated by CXCR4 ligand CXCL12 cleave 
CX3CL1 that increases the invasiveness of the individual tumor cells. 
CX3CL1 has been shown to inhibit glioma cell invasion in vitro (Sciumè et al., 2010). This 
activity of CX3CR1 may be attributed to the peculiar structure of the agonist CX3CL1 and 
may account for its ability to directly promote cell-cell adhesion when expressed as a 
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transmembrane protein therefore impeding cell motility. The effect of this CX3CR1 and 
CX3CL1 interaction was reduced by TGF-ǃ1 (Sciumè et al., 2010), which is also produced by 
glioma cells and downregulates CX3CL1 expression. The in vivo role of CX3CR1 in glioma 
growth is more complex. CXCL12 constitutively expressed in the central nervous system 
(CNS) activates CXCR4 in glioma cells to promote the cleavage of CX3CL1 into a soluble 
form that reduces the intercellular adhesion and results in the dissemination of glioma cells 
(Cook et al., 2010). Thus, it is postulated that CX3CR1 in the CNS may favor the invasion of 
glioma cells into neighboring tissues. In support of this assumption, CX3CR1 and CX3CL1 
have been reported to drive the neurotropic cancer cells to disseminate to peripheral nerves 
(Marchesi et al., 2010), a distinct but largely under appreciated route of metastasis, which 
has been shown in several tumors, including tumors of the brain, prostate, stomach, 
pancreas, bladder, and colorectum, as well as head and neck carcinoma. Thus, the balance 
between the transmembrane and soluble form plays an important role in the activity of 
CX3CL1 to either prevent or promote glioma progression (Fig. 1C).  
6. Involvement of chemoattractant GPCRs in infiltration of gliomas by 
regulatory T cells (Tregs) 
Tregs have been recognized as one of the major immune cell components that suppress host 
anti-tumor responses. Recruitment of Tregs into tumors contributes to tolerance by 
suppressing autoreactive T cells. It has been shown that Tregs infiltrate human brain tumors 
(Tran Tang et al., 2010) and preferentially accumulate in high grade malignant gliomas such 
as GBM. The importance of Tregs in the control of anti-tumor immune responses in 
experimental mouse glioma models is demonstrated by the observation that transient Treg 
depletion markedly augments the anti-tumor immunity (Tran Tang et al., 2010). Treg 
trafficking in vivo is facilitated by chemokine receptors. For instance, Treg accumulation in 
ovarian carcinoma is mediated by the chemokine receptor CCR4, which binds the ligand 
CCL22 produced in the tumor where specific T cell immunity is compromised (Curiel et al., 
2004). Analysis of lymphocyte subsets in GBM from patients shows that tumor infiltrating 
Tregs highly express CCR4 (Jacobs et al., 2010) and the ligand CCL22 is produced by GBM 
cells. But unlike ovarian carcinoma in which Treg accumulation clearly correlates with 
reduced patient survival, there is no correlation between Tregs and overall survival of GBM 
patients. Regardless, post-surgical immunotherapy has been proposed as a potentially valid 
method to eliminate residual GBM cells while preserving surrounding healthy brain cells.  
7. Chemoattractant GPCRs in gliomas as potential therapeutic targets  
Given the broad range of functions of chemoattractant GPCRs in malignant glioma 
development, progression, invasion and angiogenesis, blockage of these receptors is 
considered a novel therapeutic approach in conjunction with conventional surgical 
resection, irradiation and chemotherapy. Based on the association of CXCR4 with the 
malignant behavior of glioma, anti-CXCR4 monoclonal antibody and specific low-molecular 
weight antagonist for CXCR4 have been tested for their effects on tumor cell growth in vitro 
and in vivo. As predicted, anti-CXCR4 monoclonal antibody is able to attenuate the 
migration and proliferation of human GBM cells induced by CXCL12 (Cheng et al., 2009). In 
addition, administration of the CXCR4 antagonist AMD3100 suppressed the growth of 
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xenograft tumors formed by human GBM cells transplanted intracranially into mice, with 
increased apoptosis of the transplanted GBM cells (Rubin et al., 2003).  
Studies have also revealed the potential benefit of a combination of CXCR4 inhibitor with 
chemotherapy and radiotherapy in malignant glioma patients. In tests on a variety of GBM 
cell lines, a conventional cytotoxic chemotherapeutic agent, BCNU, in combination with the 
CXCR4 antagonist AMD3100 exhibits synergistic inhibition of tumor cell growth in vitro. In 
vivo in animal models, subtherapeutic doses of BCNU and AMD3100 also result in tumor 
regression, which is attributed to increased tumor cell apoptosis and decreased proliferation 
(Redjal et al., 2006). These effects of AMD3100 in conjunction with its capacity to reduce the 
recruitment of bone marrow EPCs to recurrent tumors post irradiation, suggest that 
targeting CXCR4 may not only directly inhibit tumor cell proliferation, but also indirectly 
abrogates neovascularization in GBMs (Kioi et al., 2010).  
Considering targeting CXCR4 as a means of inhibiting glioma, the ability of the CXCR4 
agonist CXCL12 to activate CXCR7 casts doubts about whether blockage of CXCR4 alone is 
sufficient without simultaneously inhibiting CXCR7. In fact, inhibition of CXCR4 only 
partially decreases the responsiveness of tumor cells to CXCL12 in several animal models. 
Studies have found that GSLCs express high levels of CXCR4 and low levels of CXCR7 
(Hattermann et al., 2010). In contrast, differentiation of GSLCs markedly decreased CXCR4 
expression but up-regulated CXCR7. It is therefore postulated that CXCR4 may mediate 
GSLC chemotaxis and survival, whereas differentiated glioma cells are protected from 
apoptosis by CXCR7 in response to CXCL12. It is therefore important to design strategies 
that target one or both CXCL12 receptors based on the stages of glioma cell differentiation.  
Small molecule natural compounds constitute another source of inhibition of 
chemoattractant GPCRs with therapeutic potential for gliomas (Ping et al., 2007). One of 
such compounds is Nordy, a chiral mimetic of a natural lipoxygenase inhibitor 
nordihydroguaiaretic acid. Nordy has been shown to exhibit a broad inhibitory activity on 
chemoattractant GPCRs such as CXCR4 and FPR1 on GBM cells by downregulating receptor 
expression, interfering with their signal transduction pathways and reducing tumor cell 
production of angiogenic factors VEGF and the chemokine CXCL8 (Ping et al., 2007; Chen et 
al., 2006 and 2007). In addition, Nordy has been found to inhibit GBM cell proliferation and 
to promote tumor cell differentiation into a lesser malignant phenotype. Recently, Nordy 
was found to inhibit the self-renewal of glioma stem cells and growth of xenografts 
generated by the stem cells (Wang et al., 2011). However, the effect of Nordy may not be 
specific by targeting only chemoattractant GPCRs on GBM cells. Further studies are 
required to identify more specific receptor targeting natural compounds with minimal side 
effects on key physiological cell processes.  
8. Conclusions 
There is now mounting evidence that chemoattractant GPCRs play multiple roles in the 
progression of malignant gliomas, by mediating the tumor cell growth, invasion and 
angiogenesis (Table 1). However, further molecular epidemiologic and genetic studies are 
required to obtain a better understanding of the mechanisms of the function of these 
receptors in glioma cells. It is especially important not to single out a given receptor to study 
glioma biology, but rather, studies should consider the complex host environment in which 
many factors may drive the aberrant expression of chemoattractant GPCRs and ligands. In 
addition, the interaction of chemoattractant GPCRs such as CXCR4 and FPR1 with other 
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growth factor receptors has been reported and in fact different types of the receptors 
cooperate to exacerbate the progression of malignant glioma. In addition to their direct 
effect on glioma progression, chemoattractant GPCRs expressed on immune cells also 
mediate host response to tumors by promoting recruitment of “suppresive” leukocytes 
including myeloid suppressor cells, type II macrophages and Tregs into the tumor and 
peripheral lymphoid organ to compromise anti-tumor defense. Therefore, recognition of the 
multifaceted role of chemoattractant GPCRs in gliomas and other malignant tumors in 
general is fundamental to elucidating the mechanisms of tumor progression and the 
development of novel therapeutic agents.   
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